QDEL Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Total Revenue: $620 million, with non-respiratory revenue at $552 million.
Labs Revenue: Declined 8% year-over-year, impacted by the termination of a joint business agreement and a softer respiratory season.
Respiratory Revenue: $68 million, significantly down due to a 30% decrease in influenza-like illness (ILI) visits compared to Q1 2025.
Adjusted EBITDA: $109 million, representing an 18% margin; adjusted gross profit margin decreased to 44%.
Net Loss: Diluted adjusted loss per share of $0.40.
Cash Position: $140 million in cash, with $130 million borrowed under a revolving credit facility.
Cash Flow: Operating cash flow was negative $33 million; free cash flow was negative $67 million.
Debt Leverage: Net debt to adjusted EBITDA leverage at 4.1x, with expectations to reduce to 3.25x to 3.5x by year-end.

2. Strategic Updates and Business Highlights

Acquisition: Completed the acquisition of Lex Diagnostics, enhancing capabilities in point-of-care molecular diagnostics.
Product Launches: Launched a high-sensitivity troponin assay in the U.S. and began rolling out the VITROS 450 platform in international markets.
Core Business Performance: Strong performance in core labs and immunohematology franchises, with expectations for mid-single-digit revenue growth in the labs business.

3. Forward Guidance and Outlook

2026 Revenue Guidance: Updated to a range of $2 billion to $2.75 billion, reflecting lower expectations due to the respiratory season and anticipated impacts from China's new pricing guidelines.
Adjusted EBITDA Guidance: Expected to be between $615 million and $630 million, maintaining a 23% margin.
Free Cash Flow: Projected to be $100 million to $120 million for the year, with expectations for a stronger second half.

4. Bad News, Challenges, or Points of Concern

Softer Respiratory Season: The respiratory market experienced a significant decline, impacting revenue and overall performance.
China Market Risks: Anticipated changes in national IVD pricing guidelines are causing distributors to pause purchases, which could negatively affect revenue.
Geopolitical Headwinds: Ongoing disruptions in the Middle East have delayed orders and tenders.
Cash Flow Decline: Negative cash flow in Q1 attributed to lower EBITDA and inventory increases in preparation for product launches.

5. Notable Q&A Insights

Segment Growth: Q2 expected to be flat compared to Q1 but with year-over-year growth in core segments.
China Impact: Estimated revenue impact from China is roughly $75 million, split between respiratory and China-specific challenges.
Cost Management: The company is implementing cost-saving initiatives, including staffing reductions and procurement efficiencies, to improve margins.
Lex Diagnostics Potential: Strong customer interest in the Lex platform, with low switching costs expected to facilitate adoption.

In summary, QDEL's Q1 2026 results reflect significant challenges due to a milder respiratory season and geopolitical pressures, but the company remains focused on strategic growth initiatives and expects a stronger second half of the year.

QDEL — QuidelOrtho Corporation